7.9% (10 of 126) of people taking ENHERTU achieved a complete response, meaning their HER2+ advanced stomach cancer tumor disappeared on imaging tests

A TREATMENT OPTION FOR ADULTS WITH PREVIOUSLY TREATED HER2+ ADVANCED STOMACH CANCER​

VIEW CLINICAL TRIAL RESULTS
In a clinical study of 188 people with previously treated HER2+ advanced stomach cancer, ENHERTU helped people live longer than with chemotherapy.* Among people in the trial, half of the people taking ENHERTU were alive at 12.5 months. For people taking chemotherapy, half of the people were alive at 8.4 months.† This was about 4 months longer with ENHERTU.
In the same clinical study, tumors shrank in more people treated with ENHERTU than with chemotherapy*‡:
  • 40.5% (51 of 126) of people saw a confirmed response with ENHERTU and 11.3% (7 of 62) did with chemotherapy‡§
  • 7.9% (10 of 126) of people taking ENHERTU achieved a complete response, meaning their tumor could not be seen on imaging tests. This does not always mean the cancer has been cured. No one taking chemotherapy (0 of 62) had a complete response
  • 32.5% (41 of 126) of people taking ENHERTU achieved a partial response, which means the tumor shrank by at least 30%. 11.3% (7 of 62) of those taking chemotherapy had a partial response
  • 84% (106 of 126) of people taking ENHERTU saw their tumors shrink, stop growing, or the growth of their tumors slowed, and 61% (38 of 62) of people saw this while receiving chemotherapyll
https://www.enhertu.com/en/gastric
 
40.5% (51 of 126) of people saw a confirmed response with ENHERTU and 11.3% (7 of 62) did with chemotherapy‡§
Who are the suay people in a clinical trial kena assigned to just chemotherapy? Everyone will want to try out new drugs isn’t it?
 

What is HER2+ advanced stomach cancer?​

Number One

What is HER2?HER2 is a protein that tells cells to grow. In HER2+ stomach cancer, the cancer cells have too much HER2, which leads to cancer growth
Number Two

These cells grow
and divide fasterthan healthy cells, causing tumors to form
Number Three

In advanced
stomach cancer,the cancer has started to spread to areas near the stomach or to other parts of the body
 

What is ENHERTU?​

ENHERTU is a prescription medicine used to treat adults who have:

  • stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
It is not known if ENHERTU is safe and effective in children.
 

A TREATMENT OPTION FOR ADULTS WITH PREVIOUSLY TREATED HER2+ ADVANCED STOMACH CANCER​

VIEW CLINICAL TRIAL RESULTS
In a clinical study of 188 people with previously treated HER2+ advanced stomach cancer, ENHERTU helped people live longer than with chemotherapy.* Among people in the trial, half of the people taking ENHERTU were alive at 12.5 months. For people taking chemotherapy, half of the people were alive at 8.4 months.† This was about 4 months longer with ENHERTU.
In the same clinical study, tumors shrank in more people treated with ENHERTU than with chemotherapy*‡:
  • 40.5% (51 of 126) of people saw a confirmed response with ENHERTU and 11.3% (7 of 62) did with chemotherapy‡§
  • 7.9% (10 of 126) of people taking ENHERTU achieved a complete response, meaning their tumor could not be seen on imaging tests. This does not always mean the cancer has been cured. No one taking chemotherapy (0 of 62) had a complete response
  • 32.5% (41 of 126) of people taking ENHERTU achieved a partial response, which means the tumor shrank by at least 30%. 11.3% (7 of 62) of those taking chemotherapy had a partial response
  • 84% (106 of 126) of people taking ENHERTU saw their tumors shrink, stop growing, or the growth of their tumors slowed, and 61% (38 of 62) of people saw this while receiving chemotherapyll
https://www.enhertu.com/en/gastric

How was ENHERTU studied?​

ENHERTU was studied in comparison with the doctor’s choice between 2 commonly used chemotherapies (irinotecan or paclitaxel) in 188 adults with HER2+ advanced stomach cancer.
 

How is ENHERTU thought to work?​

As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.

MOA-sequence-1.ashx

ENHERTU is made up of an antibody with the chemotherapy attached
MOA-sequence-2.ashx

The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell
MOA-sequence-3.ashx

ENHERTU enters the cancer cell and the chemotherapy is released
MOA-sequence-4.ashx

The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby
Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone.
 
Back
Top